echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > JNNP: Use a systematic method to select licensed drugs for the treatment of advanced multiple sclerosis

    JNNP: Use a systematic method to select licensed drugs for the treatment of advanced multiple sclerosis

    • Last Update: 2020-12-17
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    There are many reasons for the lack of effective treatment for advanced multiple sclerosis.
    pathophysiology of advanced multiple sclerosis is not yet known, and no animal model can accurately simulate the entire process of the disease.
    therefore, the discovery of new targets and drugs is challenging.
    drug reuse is a faster way to have fewer obstacles before entering clinical trials, but the rationale behind drug selection needs to be carefully considered.
    this paper establishes a rigorous, expert-led, evidence-based approach to evaluating licensed drugs for reuse and testing in clinical trials of patients with multiple sclerosis (MS).
    : Lists licensed drugs that have been approved by expert groups and patients with multiple sclerosis.
    we systematically reviewed the preclinical and clinical literature for each drug and, by scoring each compound, condensed it into a database of abstract documents and shortlisted drugs.
    the drug in a clinical trial and reviewed our options through a final independent expert review.
    results: Four treatment options, namely R-α-sulphate, metformin, R-α-thioic acid and metformin, were recommended from a short list of 55 courses of treatment, as well as niphosphonate.
    also gave priority to chromastin, lamotrigine, oxycasipine, nimodypine and fluorocarbons.
    drug thioic acid, which is ranked No. 1 in the drug selection program, was also listed as a priority in the 2011 drug selection plan, although the methods were different.
    Three interventions, R-α-sulphate, metformin and nihilate, as well as a joint preparation of metformin and R-α-thioic acid, were identified as priority drugs for clinical evaluation in the queue of patients with advanced multiple sclerosis, and there was sufficient data to enter phase II trials immediately.
    , Lamotrigine, Okasipine, Nimodipine and fluorocaride are also considered promising and prioritized.
    this paper, a standardized method is reported to identify candidate drugs for the treatment of advanced multiple sclerosis.
    Cunningiffe N, Vuong KA, Ainslie D, et al System approach to selecting licensed drugs for repurposing in the treatment of progressive multiple sclerosis Journal of Neurology, Neurosurgery and Psython Published Online First: 12 November 2020. doi:10.1136/jnnp-2020-324286MedSci Original Source: MedSci Original Copyright Notice: All notes on this website "Source: Met Medical" or "Source: MedSci Original" text, images and audio and video materials, copyrighted by Mace Medical, not authorized No media, website or individual may be reproduced, and authorization must be made with the "Source: Metz Medicine" in the authorizing the reprint.
    all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
    at the same time reproduced content does not represent the position of this site.
    leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.